Ibrance failed to meet the main goal of improved invasive disease free survival.
The PENELOPE-B study compared one year of Ibrance plus at least five years of standard adjuvant endocrine therapy to placebo plus at least five years of standard adjuvant endocrine therapy in 1,250 women with HR+, HER2- eBC at high risk of recurrence who have residual invasive disease after completing neoadjuvant chemotherapy.
The latest development comes after an independent data monitoring committee said in May a similar trial comparing Ibrance plus an endocrine therapy to a standalone endocrine therapy to treat early-stage breast cancer was unlikely to meet the main goal.
Ibrance is already approved in the United States to treat certain adult patients with advanced breast cancer which has spread to other parts of the body. The drug has not yet been approved for treating early stages of the disease.
This puts the drug at a relative disadvantage to rival Eli Lilly and Co, which in June posted data showing that its drug Verzenio, met the trial goal of reducing the risk of early-stage breast cancer from recurring.
"Today's data leaves Lilly's Verzenio as the clear winner in the adjuvant space for now, giving Verzenio a blockbuster opportunity in a potential early breast cancer indication," Cantor Fitzgerald analyst Louise Chen said.
By Reuters Staff
Posted on
Previous Article
« Lower risk of dementia with catheter ablation of atrial fibrillation Next Article
Baricitinib plus corticosteroids effectively treats atopic dermatitis »
« Lower risk of dementia with catheter ablation of atrial fibrillation Next Article
Baricitinib plus corticosteroids effectively treats atopic dermatitis »
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com